Sangamo Therapeutics Inc. (SGMO)
NASDAQ: SGMO
· Real-Time Price · USD
0.67
-0.00 (-0.50%)
At close: Oct 01, 2025, 3:59 PM
0.68
0.74%
Pre-market: Oct 02, 2025, 08:54 AM EDT
-0.50% (1D)
| Bid | 0.66 |
| Market Cap | 203.53M |
| Revenue (ttm) | 81.71M |
| Net Income (ttm) | -63.31M |
| EPS (ttm) | -0.26 |
| PE Ratio (ttm) | -2.59 |
| Forward PE | -2.32 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 0.72 |
| Volume | 3,150,352 |
| Avg. Volume (20D) | 5,738,396 |
| Open | 0.67 |
| Previous Close | 0.67 |
| Day's Range | 0.67 - 0.69 |
| 52-Week Range | 0.41 - 3.18 |
| Beta | 1.21 |
| Ex-Dividend Date | n/a |
About SGMO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SGMO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SGMO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsSangamo Therapeutics Inc. is scheduled to release its earnings on
Nov 11, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-38.4%
Sangamo Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
6 months ago
-4.73%
Sangamo Therapeutics shares are trading higher after the company announced it entered a capsid license agreement with Lilly.
1 month ago · seekingalpha.com
Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call TranscriptSangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alexander D. Macrae - CEO, President & Director Gregory Davis - Head of Resear...
